Proactive investors

Additional information

Additional	Information
Market:	ASX 200
Sector:	Aerospace
Epic:	ASX200
News:	Latest news
Web Site:	Australia Market Wrap
Other Articles:	02-09-201001-09-201030-08-2010

Circadian Technologies to present at Ultimate Healthcare & Biotechnology Event, March 24

by Proactive Investors

The directors of Bionomics Ltd, Pulse Health Ltd, Circadian Technologies Ltd, Medical Australia Ltd, Stirling Products Ltd, CogState Ltd and Phylogica Ltd invite you to attend at Proactive Investors' "The Ultimate Healthcare & Biotechnology Event 2010."

The event, which is free will be held at the Sydney Harbour Marriott Hotel, Sydney on Wednesday March 24, 2010 boasts leading research, scientists and executives operating in this sector.  

Think you cannot do well investing in these companies?  Yes, you can.

Many listed ASX healthcare and biotechnology companies out-performed the ASX All Ordinaries Index in 2009.

The event is also an opportunity for investors, stakeholders, industry participants to support this vital Australian sector and to network during and after the event.

After the presentations are complete the directors will also be available to meet and greet and take questions during a free Canapé and Wine Reception - to register, click here.

Bionomics Limited (ASX: BNO) is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system.

Pulse Health Limited's (ASX:PHG) focus is in the private health sector as an integrated health services provider with operations encompassing private hospitals, day surgeries and community home care.

Circadian Technologies Limited (ASX: CIR) is a biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.

Medical Australia Limited (ASX:MLA) formerly BMDi Tuta, is a medical technology company focussed on the manufacture and marketing of a broad range of medical devices used by healthcare professionals globally.

CogState Limited (ASX: CGS) is a global provider of cognitive testing products and services. CogState is currently one of the fastest growing technology companies in Australia having achieved 981% revenue growth across three years.

Stirling Products Limited (ASX: STI) is an emerging global pharmaceutical group, focussed on manufacturing, product development - pharmaceutical, botanical and OTC products, platform technology - drug delivery through inhalation and sales across the pharmaceutical, and over-the-counter markets.

Phylogica Limited (ASX:PYC) is a specialist drug discovery company, which screens the world's most structurally diverse library of biologics to identify leads for  large pharmaceutical companies. Phylogica recently inked a contract discovery agreement with Roche, one of the world’s largest pharmaceutical companies.

Investors interested in the following companies will also find the event highly beneficial:

Acrux (ASX: ACR) is an Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin.

Avexa (ASX: AVX)is an Australian drug-discovery company based in Melbourne, Victoria. Avexa's business is the discovery and development of anti-infective pharmaceutical medicines for the treatment of serious human infectious diseases. Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by Human Immunodeficiency Virus (HIV) and Vancomycin- and methicillin-resistant bacteria.

Avita Medical (ASX: AVH) is a medical device company formed through the merger of Clinical Cell Culture Ltd and Visiomed Group Ltd in February 2008. The company is active in the regenerative medicine and respiratory markets.

Benitec (ASX: BLT) is company dedicated to the development of treatments for serious human diseases including infectious diseases, neurological disorders, cancer and autoimmune diseases, through leadership in RNAi technologies and strategic partnerships with leading biopharmaceutical companies and research organisations globally.

Biota Holdings (ASX: BTA) is a leading anti-infective drug development company, based in Melbourne, Australia and Oxford, UK. Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenzaô.

Blackmores (ASX: BKL) is a distributor of branded vitamin and herbal supplements to the Australasian market. Products are distributed primarily through retail pharmacies, supermarkets, and to a lesser extent health food shops and professional outlets.

Bone Medical (ASX: BNE) is focussed on breakthrough treatments for bone and joint degeneration and disease, especially osteoporosis and arthritis.

CathrX (ASX: CXD) a specialist Australian medical device company focusing on the development and commercialisation of a range of innovative cardiac catheters for use in the diagnosis and treatment of electrical problems of the heart known as cardiac arrhythmias.

Cellestis (ASX: CST) has operations in the United States, Europe and Australia. Cellestis develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune (CMI) responses of T cell lymphocytes using whole blood samples.

Clinuvel Pharmaceuticals (ASX: CUV) is Australiaís photoprotective company. Clinuvel's focus is to gain market approval for afamelanotide, a drug to manage the symptoms of patients with severe UV and light related skin disorders.

Cochlear (ASX: COH) http://www.cochlear.com/au Cochlear is a manufacturer and marketer of cochlear implants which are used to stimulate impaired hearing. The COH implantable device is the standard for enabling profoundly hearing impaired patients to hear.

CSL (ASX: CSL) is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions. The bulk of its sales are derived from pharmaceutical and bioplasma divisions.

Genera Biosystems (ASX: GBI) is an Australian company that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera's products compete in the global market for molecular diagnostic tests - currently valued at around US$2.6 billion.

Halcygen Pharmaceuticals (ASX: HGN) operates as a licensee and developer of pharmaceutical formulations. HalcyGen, through its recent acquisition in September 2009, Mayne Pharma International, develops and registers pharmaceutical formulations known as SuperGenerics: SUBA-Itraconazole and Minocycline.

HealthLinx (ASX: HTX) is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms. HealthLinx develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™.

Hexima (ASX: HXL) is an agribusiness company developing gene technologies to help farmers enhance the productivity of arable land by improving yields and reducing the use of chemicals. Heximas core technologies aim to strengthen commercial crops by enhancing their resistance to insect pests and fungal disease.

Impedimed (ASX: IPD) is a global company with offices in Australia, the USA, and the UK. The company develops bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments that are non-invasive, compact and portable, highly accurate, fast, simple to operate, and considerably cheaper than most existing alternatives.

KarmelSonix (ASX:KSX) is a global leader in developing acoustic respiratory monitoring devices, the Companyís ground breaking products are based on acoustic signal acquisition technology and advanced analysis capabilities.

Living Cell Technologies (ASX: LCT) is a global pioneer in the development of a revolutionary new treatment for diabetes. DIABECELLÆ is LCTís treatment designed to normalise the lives of people with insulin dependent diabetes.

Mesoblast (ASX: MSB) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage.

Nanosonics (ASX: NAN) a technology driven company that is commercialising innovative and unique customer focused disinfection solutions. Nanosonics is currently focused on developing a range of infection control solutions for the healthcare industry. Nanosonicsí launch into the global market is lead by the Trophon EPR.

Novogen's (ASX: NRT) business is developing the Novogen isoflavonoid technology platform to treat degenerative diseases, such as cancer, Heart disease (stroke, hypertension, coronary artery disease) Osteoporosis, Chronic inflamatory diseases (rheumatoid arthritis, osteoarthritis, chronic back pain) and Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease).

Optiscan Imaging (ASX: OPI) has developed and patented miniaturised confocal microscopes, and is now a global leader in the development and application of microscopic imaging technologies for medical markets.

Patrys (ASX: PAB) is focused on the development of natural human antibody-based therapies for the treatment of cancer. The company is also exploring opportunities to deploy its technologies in additional indications, either internally or through third parties, including cardiovascular, autoimmune and central nervous system disorders.

Pharmaxis (ASX: PXS) is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Phosphagenics (ASX: POH) is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and personal care products (including nutraceuticals and cosmeceuticals).

Phylogica (ASX: PYC) is a biopharmaceutical company engaged in the discovery and development of novel biopharmaceuticals directed at proteins and their interactions.

Prana Biotechnology (ASX: PBT) is a world leader in addressing the role of biological metals in human disease. The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases.

PrimaBiomed (ASX: is one of the world's leaders when it comes to cancer treatment. The focus is on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of the company's fight against cancer.

Progen Pharmaceuticals (ASX: PGL) aims to maintain and develop a world-class position in the design and development of therapeutics that disrupt the protein-carbohydrate interactions involved in cancer.

pSivida Corp. (ASX: PVA) is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. The lead development product, Iluvien Æ, delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), one of the leading causes of blindness in the developed world.

QRxPharma (ASX: QRX) a clinical-stage specialty pharmaceutical company with a core focus on the development and commercialisation of pain therapy products. The Companyís lead products comprise a patented combination of existing drugs, with a well defined path to regulatory approval and sales. QRxPharmaís lead drug compound, Q8003IR, began Phase III clinical trials in 2007.

Sirtex Medical's (ASX: SRX) primary objective is to research, develop, and commercialise effective treatments for liver cancer using novel small particle technology.

Starpharma (ASX: SPL) is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications. Starpharmaís lead product is VivaGelÆ, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.

Sunshine Heart, Inc (ASX: SHC) is a global medical device company, committed to the commercialisation of C-Pulse, an implantable, non-blood contacting, heart assist therapy for the treatment of people with moderate heart failure.

Tissue Therapies (ASX: TIS) provides wound healing, tissue repair and cell culture technology through a novel growth factor platform technology, VitroGroÆ.

Tyrian Diagnostics (ASX: TDX) develops and commercialises rapid point-of-need diagnostics for clinical and non-clinical applications. Tyrianís objective is to generate recurring revenues from a portfolio of rapid point-of-need diagnostic products.

Universal Biosensors, Inc (ASX: UBI) is a specialist medical diagnostics company focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use.

Viralytics (ASX: VLA) a leading anti-cancer biotechnology company. Viralytics has acquired, by licence, an anti-cancer virotherapy technology using the naturally occurring Coxsackievirus and Echovirus. With the acquisition; Viralyticsís focus is now a leading anti-cancer biotech with a worldwide outlook.

Virax Holdings (ASX: VHL) is is a biopharmaceutical company engaged in the discovery and development of immunotherapeutic products for the treatment of chronic infectious such as Hepatitis B, autoimmune disorders, HIV/AIDS and cancers.

Vita Life Sciences (ASX: VSC) is a pharmaceutical and healthcare company, with principal activities involved in formulating, packaging, sales and distribution of vitamins and supplements and investment.

Register here to be notified of Proactiveinvestors One2One Forums.